Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer


A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer




To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.

Study Status: Terminated


Condition Intervention Phase
Lung Cancer
Non-Small Cell Lung Cancer
Drug: ABT-751
Drug: Placebo
Drug: Docetaxel
Phase 1/Phase 2

Verified by Abbott March, 2008

Sponsored by: Abbott
Information provided by: Abbott identifier: NCT00354562

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Helen Eliopoulos, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site